Age-Appropriateness of Oral Formulations Authorized for Pediatrics
Authors:
Open Access
- 16 March 2026
- journal article
- women in-pharmaceutical-research
- Published by Springer Nature in Pharmaceutical Research
- Vol. 43 (6) , 1785-1797
Abstract
Purpose: Pediatric global regulatory initiatives have come into place to address gaps in evidence-based medicine for children. Objective of this study was to assess age-appropriateness of oral pediatric formulations authorized through the U.S. Food and Drug Administration’s Pediatric Rule, Best Pharmaceuticals for Children Act and Pediatric Research Equity Act. Methods: Formulation age-appropriateness was assessed using an adapted version of the World Health Organization pediatric quality product profile assessment tool. Evaluations encompassed four product attributes across pediatric subgroups: dose and dose flexibility, patient acceptability, excipient safety and administration considerations. Each attribute was scored on a three-point scale: 1 indicating high risk, 2 moderate risk, and 3 low risk. Results: 214 oral formulations were evaluated. Age-appropriateness remains a concern; with less than one third of authorized oral formulations for neonates meeting criteria for age-appropriateness, in comparison to 66% for older pediatric populations. Tablets and capsules constitute 58% of formulations indicated for pediatrics, despite tablet sizes often being unsuitable for younger children. Liquid formulations for neonates present a significant oversight, as they frequently contain excipients of potential concern. As children age, swallowability of the dosage form appears to be deprioritized, with only 37% of unswallowable large size tablets for school-aged children, available in alternative dosage forms such as granules, or solids for dispersions. Conclusions: Significant formulation gaps persist in pediatric medicine, with acceptability and excipient safety presenting highest risk. The potential of non-conventional solid dosage forms remains underutilized, underscoring the need for regulatory frameworks to support development of pediatric medicines.Keywords
This publication has 32 references indexed in Scilit:
- Formulations in paediatric investigation plans (PIPs): Introduction to PIP quality section and regulatory frameworkInternational Journal of Pharmaceutics, 2015
- Pharmacokinetic and Pharmacodynamic Drug Interactions with Ethanol (Alcohol)Clinical Pharmacokinetics, 2014
- Pediatric formulation issues identified in Paediatric Investigation PlansExpert Review of Clinical Pharmacology, 2013
- Educational Paper: Formulation-related issues in pediatric clinical pharmacologyEuropean Journal of Pediatrics, 2012
- PEPFAR Scale-up of Pediatric HIV ServicesJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Standard 6: Age Groups for Pediatric TrialsPediatrics, 2012
- The availability and age‐appropriateness of medicines authorized for children in the NetherlandsBritish Journal of Clinical Pharmacology, 2011
- The economics of pediatric formulation development for off-patent drugsClinical Therapeutics, 2008
- Asthme et intolérance aux benzoatesArchives de Pédiatrie, 1996
- Development of Alcohol Dehydrogenase Activity in the Human LiverPediatric Research, 1967